CJC-1295 (No DAC) vs Tesamorelin

Written by the Pure Peptides editorial team

Reviewed by Dr. Martina Rossi, PhD

Scientific Contributor and Reviewer · Reviewed

Published · Updated · 9 references

CJC-1295 (No DAC) and Tesamorelin are different molecules: CJC-1295 (No DAC) is human GHRH's first 29 residues with four substitutions; Tesamorelin is an analog of the full 44-residue hormone.

CJC-1295 (No DAC)

CJC-1295 (No DAC)

View CJC-1295 (No DAC)
vs
Tesamorelin

Tesamorelin

View Tesamorelin

Structure at a glance

Each chain as stored in the product database, one box per residue. The two are drawn separately; no alignment between them is implied.

CJC-1295 (No DAC) · 29 residues

Tesamorelin · 44 residues

Hex: N-terminal trans-3-hexenoyl group. NH2: C-terminal amide. A raised D marks a D-amino acid. Codes are three-letter amino acid codes.

Chain length
CJC-1295 (No DAC)29 residues
Tesamorelin44 residues
Molecular weight
CJC-1295 (No DAC)3,367.97 g/mol
Tesamorelin5,135.86 g/mol

Drawn from the product database. Each measure's bars share one scale.

CJC-1295 (No DAC) vs Tesamorelin, compared
What it isA synthetic analog of growth hormone-releasing hormone. Built on the GRF(1-29) backbone, with four amino acid substitutions.[1]A 44-residue peptide: a synthetic analog of human growth hormone-releasing hormone with an N-terminal trans-3-hexenoyl group.
How they relateTwo molecules derived from the same parent, human growth hormone-releasing hormone. CJC-1295 (No DAC) is built on its first 29 residues, with four substitutions; Tesamorelin is an analog of the full 44-residue hormone.
CAS number446036-97-1218949-48-5
Molecular formulaC152H252N44O42C221H366N72O67S
Molecular weight3,367.97 g/mol5,135.86 g/mol
SequenceTyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2trans-3-hexenoyl-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2
TargetThe GHRH receptor, a class B G protein-coupled receptor on anterior pituitary somatotrophs.The pituitary GHRH receptor.
Evidence baseIn the literature reviewed for CJC-1295 (No DAC), the pharmacokinetic findings were generated with the DAC form. Essentially uncharacterized in humans.[2]Human studies, which supported an approval for one indication. A pooled analysis of two phase 3 trials covered 806 randomized participants.[3] Their primary endpoints were imaging surrogates. The trial papers were manufacturer-sponsored.
Regulatory statusNo approved product in the United States, the European Union or 12 other countries FDA checked.[9]The FDA approved tesamorelin acetate in 2010 for one therapeutic indication.[4][5] That approval is current.
Compared head-to-head?No direct comparison found in PubMed (searched October 2026).[6]
Handling differenceCJC-1295 (No DAC) contains no sulfur, so it carries neither methionine nor cysteine. Tesamorelin contains one methionine, which oxidizes on air exposure, and no cysteine.

How CJC-1295 (No DAC) and Tesamorelin differ

CJC-1295 (No DAC) and Tesamorelin are different molecules derived from the same parent, human growth hormone-releasing hormone (GHRH), a 44-residue hypothalamic hormone. CJC-1295 (No DAC) corresponds to the hormone's first 29 residues, the stretch named GRF(1-29), with four of those positions substituted. It is also sold as Modified GRF(1-29), a name that states that construction more plainly. Tesamorelin is an analog of the full 44-residue hormone, with a trans-3-hexenoyl group on its N-terminus. Both act at the GHRH receptor, a class B G protein-coupled receptor on the somatotroph cells of the anterior pituitary.

In the literature reviewed for CJC-1295 (No DAC), the pharmacokinetic findings, in rats and healthy volunteers, came from CJC-1295 with DAC, whose albumin-binding linker CJC-1295 (No DAC) lacks. CJC-1295 (No DAC) itself is essentially uncharacterized in humans.[2] The literature reviewed for CJC-1295 (No DAC) reports no human safety data for CJC-1295 (No DAC) itself. In the literature reviewed for Tesamorelin, a pooled analysis of its two phase 3 trials covered 806 randomized participants.[3] The two trials' primary endpoints were imaging surrogates, not clinical outcomes. The two trial papers and the pooled analysis were manufacturer-sponsored, with sponsor-affiliated co-authors. In the first of the two randomized placebo-controlled phase 3 trials, withdrawal because of an adverse event was higher on Tesamorelin than on placebo.[7]

FDA's 2024 review found no approved product containing any form of CJC-1295 in the United States, the European Union or 12 other countries.[9] The FDA approved tesamorelin acetate in 2010 for one therapeutic indication.[4][5] That approval is current. It belongs to tesamorelin acetate and that one indication, is not a family credential, and says nothing about other GHRH analogs. Tesamorelin acetate is the active ingredient of a prescription medicine sold under another name. The material supplied here is a research-grade preparation, is not that medicine, and holds no marketing authorization. That medicine's label lists glucose intolerance or new diabetes among its warnings; HbA1c reached 6.5% or above in 5% of participants on the drug against 1% on placebo.[8]

CJC-1295 (No DAC) contains no sulfur, so it carries neither methionine nor cysteine, and no disulfide or sulfoxide can form. Tesamorelin contains a single methionine, which oxidizes to a sulfoxide on air exposure, and no cysteine, so no disulfide is possible. Both contain residues that deamidate, and both can aggregate.

Have CJC-1295 (No DAC) and Tesamorelin been compared directly?

No direct comparison of CJC-1295 (No DAC) with Tesamorelin was found in a PubMed search run in October 2026.[6] That search covers PubMed only.

Read more on each compound

Frequently Asked Questions

Is CJC-1295 (No DAC) the same as Tesamorelin?+

CJC-1295 (No DAC) and Tesamorelin are different molecules derived from the same parent, human growth hormone-releasing hormone. CJC-1295 (No DAC) is built on that hormone's first 29 residues, with four amino acid substitutions. Tesamorelin is an analog of the full 44-residue hormone, with a trans-3-hexenoyl group on its N-terminus.

Is CJC-1295 (No DAC) or Tesamorelin approved?+

CJC-1295 (No DAC) has no US approval, while tesamorelin acetate is the active ingredient of a prescription medicine sold under another name. The material supplied here is a research-grade preparation, is not that medicine, and holds no marketing authorization. The FDA approval behind that medicine belongs to tesamorelin acetate and one indication.

References

  1. 1
    Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al. Endocrinology. 2005;146(7):3052-3058. doi:10.1210/en.2004-1286. PMID 15817669.
  2. 2
    Dominikowski A, et al. Front Endocrinol (Lausanne) 2026. PMID 42395176. DOI 10.3389/fendo.2026.1822475. Narrative review.
  3. 3
    Pooled analysis of two phase 3 trials, 2010. PMID 20554713.
  4. 4
    US Food and Drug Administration, Center for Drug Evaluation and Research. Approval letter for tesamorelin, 10 November 2010 (Reference ID 2863003).
  5. 5
    US Food and Drug Administration, Drugs@FDA. Approval record whose active ingredient is tesamorelin acetate; marketing status Prescription. Retrieved via api.fda.gov/drug/drugsfda.json on products.active_ingredients.name "TESAMORELIN ACETATE", 3 October 2026.
  6. 6

    PubMed search, 3 October 2026 (records to 2 October 2026)

    15 records; none was a direct comparison of the two compounds.

    Exact query (NCBI E-utilities): ("CJC-1295"[tiab] OR "CJC 1295"[tiab] OR "CJC1295"[tiab] OR "modified GRF"[tiab] OR "mod GRF"[tiab] OR "modGRF"[tiab] OR "tetrasubstituted"[tiab] OR "DAC-free"[tiab] OR "non-DAC"[tiab] OR "without DAC"[tiab] OR "no DAC"[tiab]) AND ("tesamorelin"[tiab] OR "hexenoyl"[tiab] OR "trans-3-hexenoyl"[tiab]) AND ("1800/01/01"[edat] : "2026/10/02"[edat])

    View this search on PubMed
  7. 7
    Phase 3 trial report, 2007. PMID 18057338.
  8. 8
    US Food and Drug Administration. Approved prescribing information for tesamorelin acetate; label version 29 July 2026. Retrieved via openFDA drug/label.
  9. 9
    US Food and Drug Administration, Center for Drug Evaluation and Research. Briefing document, 4 December 2024. Regulatory document, not peer-reviewed. fda.gov
Dr. Martina Rossi, PhD

Reviewed for scientific accuracy

Dr. Martina Rossi, PhD

PhD, Université Grenoble Alpes · Scientific Contributor and Reviewer

Dr. Rossi's doctoral research at Université Grenoble Alpes examined the vascular functions of bone morphogenetic proteins. Her peer-reviewed work spans cell and molecular biology, vascular biology, and gene therapy, in journals including Cardiovascular Research, Scientific Reports, and Brain Sciences. She reviews Pure Peptides' product, reference, and research pages for scientific accuracy against the sources they cite.

Reviewed ORCIDGoogle ScholarTeam profile →
Comparison

AOD-9604 vs Tesamorelin

AOD-9604 is a modified 16-residue peptide from the C-terminal end of human growth hormone; Tesamorelin is a 44-residue analog of human GHRH.

Read Comparison
Comparison

CJC-1295 (No DAC) vs CJC-1295 with DAC

CJC-1295 with DAC is a chemically modified form of CJC-1295 (No DAC); the DAC-free peptide is essentially uncharacterized in humans.

Read Comparison
Comparison

CJC-1295 (No DAC) vs IGF-1 LR3

CJC-1295 (No DAC), a 29-residue peptide, and IGF-1 LR3, an 83-residue protein, are different molecules from different parents.

Read Comparison